ArticlePloS one2025
Musa Paradisiaca derived intrinsically heteroatom doped carbon dots as antioxidant and controlled drug release behavior.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This work presents a green, single-step hydrothermal synthesis of intrinsically nitrogen-doped Carbon dots (MCDs) derived from Musa paradisiaca, a low-cost and renewable biomass source. The eco-friendly synthesis avoids external dopants or harsh chemicals, offering a scalable and sustainable alternative to conventional multistep methods. The resulting MCDs, with an average particle size of 4.2 nm (TEM), display desirable surface functionalities (FTIR, XPS) and heteroatom doping. Optical characterization revealed a broad UV-vis absorption at 280 nm and strong blue photoluminescence at 440 nm. DLS and zeta potential measurements confirmed excellent colloidal stability. The MCDs demonstrated high antioxidant activity (>80% radical scavenging) and biocompatibility in cellular assays. Moreover, they enabled controlled drug release, underlining their promise as multifunctional nanocarriers. Given their green synthesis, stability, and performance, these MCDs are highly suitable for future biomedical and clinical applications, particularly in antioxidant therapy and targeted drug delivery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.